Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 15/20 | 0.76 |
| ▸ | MAPK8 | P45983 | 12/20 | 0.76 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.52 |
| ▸ | JUN | P05412 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182609 | 0.88 | MAPK9 (0.72) | MAPK9MAPK8MAPK10JUNCDK2 | |
| SCHEMBL7884776 | 0.86 | MAPK9 (1.00) | MAPK9MAPK8MAPK10JUNCDK2 | |
| SCHEMBL182355 | 0.86 | MAPK9 (1.00) | MAPK9MAPK8MAPK10JUNCDK2 | |
| SCHEMBL184151 | 0.84 | MAPK9 (0.77) | MAPK9MAPK8MAPK10JUNCDK2 | |
| SCHEMBL183139 | 0.76 | MAPK9 (0.79) | MAPK9MAPK8MAPK10JUNCDK2 | |
| SCHEMBL183210 | 0.74 | MAPK9 (0.81) | MAPK9MAPK8MAPK10FLT3 | |
| SCHEMBL27851060 | 0.73 | MAPK8 (0.45) | MAPK9MAPK8MAPK10JUNCDK2 | |
| SCHEMBL7884533 | 0.72 | MAPK9 (1.00) | MAPK9MAPK8MAPK10JUNCDK2 | |
| SCHEMBL182900 | 0.72 | MAPK9 (1.00) | MAPK9MAPK8MAPK10JUNCDK2 | |
| SCHEMBL183339 | 0.71 | MAPK9 (1.00) | MAPK9MAPK8MAPK10JUNCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401274-B1 | IMIDAZO[1,2-A]PYRIDINES AS JNK MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-8569306-B2 | JNK modulators | HOFFMANN-LA ROCHE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2401274-A1 | IMIDAZO [1, 2 -A]PYRIDINES AS JNK MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| US-20110306618-A1 | JNK Modulators | BUETTELMANN BERND (DE) | 2011-12-15 | — | — | US | disclosed |
| WO-2010097335-A1 | IMIDAZO [1, 2 -A] PYRIDINES AS JNK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306618-A1 | JNK Modulators | MAPK3, MAPK1, MAPK4 | MAPK9 15/4885MAPK8 11/4885MAPK10 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.